November 24, 2012 | Saturday | Analysis | By BioSpectrum Bureau
4th Annual BioSpectrum-CMR Survey' of contract and clinical research organizations (CRO) 2012
Would patent expiry of major monoclonal antibodies (mAbs) impact the pharma market soon?